Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15621990 | 0.97 | MEN1 (0.60) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL6685962 | 0.86 | CLK4 (0.64) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL16625771 | 0.83 | CLK4 (0.61) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL3625738 | 0.79 | MEN1 (0.77) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL195814 | 0.77 | MEN1 (0.60) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL14422990 | 0.77 | MEN1 (0.82) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL5586458 | 0.77 | NPC1 (1.00) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL4303322 | 0.77 | MEN1 (0.56) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL29637613 | 0.76 | CLK4 (0.54) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL29637614 | 0.76 | CLK4 (0.54) | MEN1KMT2ANPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773552-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2019191229-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | claimed |
| CN-100345830-C | Condensed heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2007-10-31 | — | — | CN | claimed |
| CN-1629145-A | Condensed heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2005-06-22 | — | — | CN | claimed |
| CN-1426398-A | Fused heteroaryl derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 2003-06-25 | — | — | CN | claimed |
| WO-2024078392-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-04-18 | — | — | WO | disclosed |
| EP-4330233-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11780839-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| EP-3626699-B1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-110352188-B | Fluoroallylamine derivatives and use thereof | 四川科伦博泰生物医药股份有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-114901086-A | Tobacco treatment | 英美烟草(投资)有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-1326494-A | Chiral liquid crystal compounds having fluorinated terminal portion | MINNESOTA MINING & MFG (US) | 2001-12-12 | — | — | CN | disclosed |
| EP-1135450-A1 | CHIRAL LIQUID CRYSTAL COMPOUNDS HAVING A FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2001-09-26 | — | — | EP | disclosed |
| CN-1283193-A | Liquid crystal compounds having chiral fluorinated terminal portion | MINNESOTA MINING & MFG (US) | 2001-02-07 | — | — | CN | disclosed |
| WO-2000031210-A1 | CHIRAL LIQUID CRYSTAL COMPOUNDS HAVING A FLUORINATED TERMINAL PORTION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
| US-5849216-A | Compounds for use in liquid-crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| EP-0541081-A2 | Compounds with only a side chain for use in liquid crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-05-12 | — | — | EP | disclosed |
| EP-0352480-A2 | Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same | CANON KABUSHIKI KAISHA (JP) | 1990-01-31 | — | — | EP | disclosed |
| EP-0347943-A2 | Ferroelectric chiral smectic liquid crystal composition and liquid crystal device using same | CANON KABUSHIKI KAISHA (JP) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | MEN1 1334/4885KMT2A 1048/4885NPC1 83/4885 |
| US-11780839-B2 | Compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | MEN1 1334/4885KMT2A 1048/4885NPC1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.